Results 21 to 30 of about 3,654 (190)

Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) micro‐elimination faces challenges from fragmented care pathways, particularly in high‐prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified ‘Test and Treat’ (TNT) strategy to enhance in‐hospital HCV micro‐elimination by reducing delays and improving linkage to care ...
You C, Diao Y, Tang J, Tang J, Deng W, Zheng C, Liao D, Song D, Wang J, Pu Y.   +9 more
europepmc   +2 more sources

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

JGH Open, 2023
Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes.
Chee‐Kiat Tan, Xue‐Shi Luo, Benjamin Shao‐Kiat Ong, Liang Lin, Kwong‐Hoe Ng   +4 more
doaj   +1 more source

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt [PDF]

Delta Journal of Science, 2023
Hepatitis C is caused by the hepatitis C virus. Various treatments for hepatitis C were ineffective before the use of direct-acting antivirals (DAAs). DAA has few (negative) adverse effects and high sustained virologic response rate (SVR12).
wessam ragab, Eman Fares, Heba Eldash, Naglaa Ismael, Ahmed Gomaa   +4 more
doaj   +1 more source

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

PLoS ONE, 2023
BackgroundHepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually.
Ashish Awasthi, Harshita Katiyar, Sumit Rungta, Amar Deep, Vinod Kumar, Shalimar, Ajay Kumar, Prachi Tiwari, Amit Goel   +8 more
doaj   +1 more source

TDM-guided Crushed Sofosbuvir-velpatasvir Treatment: A case study

, 2020
International audienceIn this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg).
Charlotte Pronier, Verdier, Marie-Clémence, Tron, Camille, Guyader, Dominique, Caroline Jézéquel, Pronier, Charlotte, Florian Lemaitre, Mercerolle, Marion, Camille Tron, Lalanne, Sébastien, Dominique Guyader, Lemaitre, Florian, Jezequel, Caroline, Sébastien Lalanne, Marion Mercerolle, Marie-Clémence Verdier   +15 more
core   +1 more source

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs

PLoS ONE, 2023
Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L. Zullig   +3 more
doaj   +3 more sources

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis

The Korean Journal of Gastroenterology, 2016
Articles: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection (N Engl J Med 2015;373:2599-2607) Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection (N Engl J Med 2015;373:2608-2617)
Ki Tae Yoon
doaj   +1 more source

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

, 2018
In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and ...
Pineda, Juan A, Casado, Marta, Calleja, Jose Luis, Rivero, Antonio, McNabb, Brian, Subramanian, G Mani, Esteban, Rafael, Stamm, Luisa M, Buti, Maria, Rodriguez, Manuel, Pascasio-Acevedo, Juan Manuel, Morillas, Rosa Maria, Carrion, Jose Antonio, Riveiro-Barciela, Mar, Camus, Gregory, Brainard, Diana M, Morano-Amado, Luis Enrique, Andrade, Raul J, Zhang, Gulan, Forns, Xavier, Turnes, Juan, Lens, Sabela   +21 more
core   +2 more sources

Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi

Pakistan Journal of Medicine and Dentistry, 2020
Background: Pakistan has approximately eight million Hepatitis C Virus (HCV) infected patients. Initial regimen of interferon-based along with ribavirin showed SVR (Sustained Virological Response Rate) of up to 50%.
Samia Perwaiz Khan, Muslim Abbas, Ajeet Kumar, Fadieleh A. Sohail, Rubina Ghani   +4 more
doaj   +1 more source